The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · May 2019
Randomized Controlled Trial Multicenter StudyAssessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
Mepolizumab has demonstrated favorable safety and efficacy profiles in placebo-controlled trials of 12 months' duration or less; however, long-term data are lacking. ⋯ These data support the long-term safety and efficacy of mepolizumab in patients with SEA.